Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involved
Eligibility Criteria
Inclusion Criteria: Age ≥ 12 years * Therapeutic indication for taking one of the following drugs for the treatment of obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®), Tirzepatide (Mounjaro®) Exclusion Criteria: - Type 1 and type 2 diabetes mellitus \- Secondary forms of obesity: * Hypothalamic obesity (both monogenic and acquired forms); * Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl, etc.); * Endocrinopathies associated with obesity (Cushing's syndrome, uncompensated hypothyroidism)